Caffeine

WEDNESDAY, Jan. 7, 2026 — For decades, doctors assumed ADHD medications like Ritalin and Adderall work by fixing problems in the brain’s attention system. A new study suggests that assumption may be wrong. Instead of acting on attention centers, these stimulant drugs appear to target the brain’s reward and wakefulness centers, according to new research published in the journal Cell . “When I first saw the results, I thought I had just made a mistake because none of the attention systems are changing here,” study author Dr. Benjamin Kay , a professor of neurology at Washington University School of Medicine in St. Louis, told The Washington Post. The researchers analyzed brain scans from nearly 5,800 8- to 11-year-olds who took part in the long-running Adolescent Brain Cognitive Development study. Some had taken prescription stimulants on the day of their scan. Others had not. When scientists compared the two groups, they found clear differences — but not where they expected. The drugs increased activity in brain regions tied to reward and wakefulness, not attention. That doesn’t mean the medications don’t help. “The paper clearly shows that they help,” study co-author Dr. Nico Dosenbach told The Post. “They help kids who have a diagnosis of ADHD do better in school and do better on tests, and they help kids who don’t sleep enough ― and a lot of Americans don’t sleep enough.” Dosenbach, who is also a professor of neurology at Washington University, explained that the drugs may help by making boring tasks feel more rewarding. They “pre-reward our brains and allow us to keep working at things that wouldn’t normally hold our interest,” he added. ADHD affects an estimated 7 million U.S. children ages 3 to 17, and about 15.5 million adults. Rates among children rose from 6.1% in the late 1990s to more than 10% by 2016, one study found. The new study also highlighted the role of sleep. The stimulants not only helped kids with ADHD, but also children without an ADHD diagnosis who slept less than the recommended nine hours a night. But the medications didn't improve school performance in children who slept well and did not have ADHD. In short, sleep matters a lot, experts said. “Despite the name ‘Attention Deficit,’ ADHD is a multifaceted disorder in which difficulty focusing attention is just one component,” said Maggie Sweitzer , a psychiatry professor at Duke University School of Medicine in Durham, North Carolina, who reviewed the findings. "It’s important to remember that ADHD is not a benign condition — individuals with ADHD are not only at risk for school problems in childhood, but also for occupational, social, and physical, and mental health problems across the lifespan. For many people these medications are transformative," Sweitzer added. Jessica Lunsford-Avery , a child development and behavioral health specialist at Duke, also reacted to the findings. “Sleep disturbances are incredibly common in ADHD, impacting about 3 out of 4 children and adolescents with the disorder,” she told The Post in an email . “It is increasingly clear that clinicians and families should view ADHD as a 24-hour disorder," Lunsford-Avery added. "Unfortunately, sleep problems are rarely recognized or adequately treated in children and adolescents with ADHD.” Doctors emphasize that prescription stimulants are not the same as energy drinks or caffeine. Dr. Sinan Omer Turnacioglu of Children’s National Hospital in Washington, D.C., noted that prescription stimulants “don’t work in the exact same way in the nervous system.” He added that healthy sleep habits such as limiting screen time before bed and having a calming routine are important. Sources The Washington Post, Jan. 6, 2026

来源：新浪证券-红岸工作室1月6日，新诺威涨1.26%，成交额4.97亿元，换手率0.94%，总市值532.62亿元。异动分析减肥药+创新药+生物疫苗+维生素+回购增持再贷款概念1、2024年10月19日公告，新诺威拟通过发行股份及支付现金方式购买石药集团下属的维生药业、石药上海、恩必普药业三家公司合计持有的石药百克 100%股权。石药百克GLP-1 产品方面，TG103 注射液（创新型长效重组人源胰高血糖素样肽-1（GLP-1）Fc 融合蛋白）、司美格鲁肽注射液（长效胰高糖素样肽-1（GLP-1）类似物）的超重/肥胖和 2 型糖尿病适应症正在进行 III 期临床，预计从 2026 年起陆续获批上市。此外还有包括司美格鲁肽长效注射液（流体晶剂型）、GLP-1 口服小分子片剂以及双靶、三靶产品等临床前阶段的全面布局。2、2023年9月12日公告：公司对石药集团巨石生物增资，增资完成后，公司可凭借巨石生物在创新药领域的研发实力，进入生物创新医药的前沿领域，实现研发实力和产品结构的跨越发展，为将公司打造成为领先的创新驱动型生物医药平台奠定了坚实的基础。3、根据2024年年报：公司的主营业务为生物制药和功能食品及原料的研发、 生产和销售。 生物制药聚焦于 ADC、mRNA 疫苗以及抗体类药物等前沿领域, 已搭建了专业的生物医药创新产业平台； 功能食品及原料包括咖啡因、 维生素 C 含片等。4、2023年5月15日互动易：目前公司已有多款维生素类保健食品生产销售，2022年度保健食品类产品实现销售收入3.29亿。5、2025年5月8日公告，石药创新制药股份有限公司控股股东恩必普药业计划增持公司股份，增持金额不低于1亿元，不超过1.2亿元，资金来源为自有资金与增持专项贷款，贷款银行为渤海银行，贷款金额不超过8400万元。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入-1133.67万，占比0.02%，行业排名123/158，该股当前无连续增减仓现象，主力趋势不明显；所属行业主力净流入-9.48亿，当前无连续增减仓现象，主力趋势不明显。区间今日近3日近5日近10日近20日主力净流入-1133.67万6766.90万9199.62万1.04亿1.10亿 主力持仓主力没有控盘，筹码分布非常分散，主力成交额1.34亿，占总成交额的6.31%。技术面：筹码平均交易成本为39.11元该股筹码平均交易成本为39.11元，近期该股有吸筹现象，但吸筹力度不强；目前股价在压力位39.56和支撑位35.41之间，可以做区间波段。公司简介资料显示，石药创新制药股份有限公司位于河北省石家庄市栾城区张举路62号,香港湾仔港湾道18号中环广场32楼3206室，成立日期2006年4月5日，上市日期2019年3月22日，公司主营业务涉及功能食品的研发、生产与销售。主营业务收入构成为：功能食品及原料88.93%，生物制药8.91%，其他2.16%。新诺威所属申万行业为：医药生物-化学制药-原料药。所属概念板块包括：融资融券、大盘、基金重仓、维生素、创新药等。截至12月10日，新诺威股东户数2.43万，较上期增加4.36%；人均流通股57704股，较上期减少4.17%。2025年1月-9月，新诺威实现营业收入15.93亿元，同比增长7.71%；归母净利润-2404.89万元，同比减少117.26%。分红方面，新诺威A股上市后累计派现6.51亿元。近三年，累计派现5.00亿元。机构持仓方面，截止2025年9月30日，新诺威十大流通股东中，香港中央结算有限公司位居第二大流通股东，持股1778.22万股，相比上期减少321.69万股。中欧医疗健康混合A（003095）位居第三大流通股东，持股1632.25万股，相比上期减少386.14万股。工银前沿医疗股票A（001717）位居第四大流通股东，持股1400.01万股，相比上期增加200.01万股。汇添富创新医药混合A（006113）位居第五大流通股东，持股1227.70万股，相比上期增加248.44万股。易方达创业板ETF（159915）位居第九大流通股东，持股786.80万股，相比上期减少132.53万股。中银创新医疗混合A（007718）位居第十大流通股东，持股639.69万股，为新进股东。中欧医疗创新股票A（006228）退出十大流通股东之列。风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建议。返回搜狐，查看更多